Pramodini Medicare IPO
Market Sentiment
IPO Details
Market Lot Size
IPO Reservation
Day-wise Subscription (times subscribed)
Financial Analysis
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 35.79 | 38.55 | 63.38 |
| Expense | 25.72 | 22.80 | 40.08 |
| Profit (PAT) | 7.14 | 11.14 | 17.38 |
| Total Assets | 48.78 | 56.45 | 93.62 |
| Company | EPS | P/E | RoNW % | NAV |
|---|---|---|---|---|
| Invicta Diagnostic Limited | 4.90 | 13.62 | 9.76 | 39.71 |
| Krsnaa Diagnostics Limited | 31.30 | 16.74 | 10.35 | 302.23 |
| Star Imaging & Path Labs Limited | 11.05 | 7.87 | 16.58 | 66.65 |
Promoters: Dr. Chalasani Kuldeep Kumar, Dr. Chalasani Kavitha, Ms. Chalasani Durga Aashritha and M/s. Sri Ram Medicare Private Limited
Strengths & Risks
- Strongly subscribed — 4.0x overall (so far).
- Strong institutional (QIB) demand — 3.7x.
- Revenue grew 64% in the latest reported year.
- Solid profit margin — 27.4%.
- Strong return on equity — 39%.
Our metrics didn't flag a major concern for Pramodini Medicare from the disclosed data — but this isn't a clean bill of health. Read the risk-factors section of the RHP, which lists company-specific risks our data can't capture.
Compiled from this issue's live GMP, subscription, valuation and financial data, and updated as those figures change. Informational only — not investment advice. Always read the RHP before applying.
Company Information
Pramodini Medicare Limited, founded in 2000, is one of the leading diagnostic services providers in India across radiology, clinical laboratory, and nuclear medicine segments. Its service portfolio includes radiology services such as MRI, CT scans, X-ray, ultrasound with colour Doppler, mammography, DEXA scan, and interventional radiology; clinical laboratory services including haematology, microbiology, immunology, pathology, and biochemistry; and nuclear medicine services such as PET-CT, SPECT, and nuclear therapy. Pramodini Medicare operates diagnostic centres through Public-Private Partnerships (PPP), Private-Private Partnerships (Pvt-Pvt), Strategic Partnerships with PSUs, Standalone Diagnostic Centres, and Location-Specific Agreements. The firm has its presence across Vijayawada, Hyderabad, Kurnool, Kapada, Tirupati, Varanasi, Prayagraj, and many others.
Pramodini Medicare Ltd., D. No: – 29-4-54K, CSI Complex,, Prakasam Road,, Suryaraopet, Vijayawada, Andhra Pradesh, 520002
| Purpose | Amount (Cr) |
|---|---|
| Funding of capital expenditure for purchase of Medical Equipments towards Existing and Proposed Diagnostic Centres | 45.15 |
| General corporate purposes and unidentified inorganic acquisition | - |
Resources & Documents
Pramodini Medicare has set a price band of Rs 110–Rs 118 per share for an issue size of Rs 69 crore. The stock listed with a 1.69% gain versus its issue price on August 19, 2026.
Pramodini Medicare Limited, founded in 2000, is one of the leading diagnostic services providers in India across radiology, clinical laboratory, and nuclear medicine segments. Its service portfolio includes radiology services such as MRI, CT scans, X-ray, ultrasound with colour Doppler, mammography, DEXA scan, and interventional radiology; clinical laboratory services including haematology, microbiology, immunology, pathology, and biochemistry; and nuclear medicine services such as PET-CT, SPECT, and nuclear therapy.
The issue is promoted by Dr. Chalasani Kuldeep Kumar, Dr. Chalasani Kavitha, Ms. Chalasani Durga Aashritha and M/s. Sri Ram Medicare Private Limited with Smart Horizon Capital Advisors Pvt.Ltd. acting as lead manager. Net proceeds will primarily be used towards Funding of capital expenditure for purchase of Medical Equipments towards Existing and Proposed Diagnostic Centres (Rs 45 crore) and General corporate purposes and unidentified inorganic acquisition.
Final subscription data records overall subscription at 3.95x, retail at 3.47x, QIB at 3.66x, NII at 5.31x.
On fundamentals, the company is posting revenue growth of 64.4%, a profit margin of 27.4%, return on equity of 39.1% in its most recent reported period. Listed peers in this segment include Invicta Diagnostic Limited (P/E 13.62x) and Krsnaa Diagnostics Limited (P/E 16.74x) — useful reference points when evaluating the issue's pricing relative to where the broader sector are trading.
Our data-driven engine currently flags this issue as a Neutral stance — the data is mixed and the risk-reward is balanced rather than one-sided. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Pramodini Medicare IPO GMP — What It Means
No active grey market premium has been recorded for Pramodini Medicare IPO yet. GMP is an unofficial, dealer-quoted indicator of expected listing-day demand — not a guaranteed listing price — and it can change quickly once bidding opens.
See the full Pramodini Medicare GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
No comments yet. Be the first to share your opinion!